Criteria to qualify for study: Drug used in study:
  • Documentation of CD19 expression; ECOG of 0 or 1

ALL 06

An Open-Label, Muti-Centre, Phase lb/ll study evaluating the safety and efficacy of Auto1, A CAR-T Cell treatment targeting CD19 in adult patients with relapsed of refractory B Cell Acute Lymphoblastic Leukemia.

Criteria to qualify for study: Drug used in study:
  • Confirmed NHL, i NHL or ALL; evidence of CD19 expression

HR 62

A Phase ½ open label clinical trial of TC-100 T Cells in adults with relapsed or refractory Non Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia